Clearmind Medicine (NASDAQ:CMND) Major Shareholder Financial Lp Hrt Acquires 2,159,052 Shares of Stock

Clearmind Medicine Inc. (NASDAQ:CMND) major shareholder Financial Lp Hrt purchased 2,159,052 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were acquired at an average cost of $0.15 per share, with a total value of $323,857.80. Following the completion of the purchase, the insider directly owned 2,063,266 shares in the company, valued at $309,489.90. The trade was a -2,254.04% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, June 11th, Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock. The stock was sold at an average price of $0.12, for a total value of $27,022.92.

Clearmind Medicine Stock Performance

Shares of CMND stock opened at $3.34 on Friday. Clearmind Medicine Inc. has a 52-week low of $2.10 and a 52-week high of $524.00. The firm has a market capitalization of $3.41 million, a P/E ratio of -0.02 and a beta of 0.64. The stock has a 50 day moving average price of $6.22 and a 200 day moving average price of $16.92.

Clearmind Medicine (NASDAQ:CMND) last issued its earnings results on Thursday, March 12th. The company reported ($33.20) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Clearmind Medicine to a “sell” rating in a research report on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.